H.C. Wainwright Remains a Buy on Bausch + Lomb Corporation (BLCO)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation today and set a price target of $20.00.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Chen covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Opko Health, and CareDx. According to TipRanks, Chen has an average return of 0.2% and a 40.89% success rate on recommended stocks.

In addition to H.C. Wainwright, Bausch + Lomb Corporation also received a Buy from Citi’s Joanne Wuensch in a report issued on April 30. However, on the same day, Stifel Nicolaus maintained a Hold rating on Bausch + Lomb Corporation (NYSE: BLCO).

Based on Bausch + Lomb Corporation’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.24 billion and a GAAP net loss of $71 million. In comparison, last year the company earned a revenue of $1.14 billion and had a GAAP net loss of $212 million

Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLCO in relation to earlier this year. Most recently, in March 2026, Sam Eldessouky, the EVP & CFO of BLCO bought 4,000.00 shares for a total of $68,520.00.